From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...

Researchers at Karolinska Institutet have discovered new insights into brain changes in Parkinson's disease using advanced ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Danish film director Lars von Trier has been admitted to a care facility for Parkinson’s disease, his producer said Wednesday ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

The 65-year-old singer, whose “Walking in Memphis” single took the world by storm in the early ’90s, has Parkinson’s disease — a secret he revealed to fans on Thursday, January 31 ...

The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Jan. 21, 2025 — The B vitamin mitigates manganese neurotoxicity, which produces symptoms that resemble Parkinson's disease. The vitamin improves dopamine production in the brain and offers ...

Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...